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Background: To ensure a correct interpretation of results obtained with quantitative real-time reverse transcription-
polymerase chain reaction (RT-qPCR), it is critical to normalize to a reference gene with stable mRNA expression in
the tissue of interest. GADPH is widely used as a reference gene in ovarian tumour studies, although lacking
tissue-specific stability. The aim of this study was to identify alternative suitable reference genes for RT-qPCR studies
on benign, borderline, and malignant ovarian tumours.
Methods: We assayed mRNA levels for 13 potential reference genes – ABL1, ACTB, CDKN1A, GADPH, GUSB, HPRT1,
HSP90AB, IPO8, PPIA, RPL30, RPL4, RPLPO, and TBP –with RT-qPCR in 42 primary ovarian tumours, using
commercially pre-designed RT-qPCR probes. Expression stability was subsequently analysed with four different
statistical programs (GeNorm, NormFinder, BestKeeper, and the Equivalence test).
Results: Expression of IPO8, RPL4, TBP, RPLPO, and ACTB had the least variation in expression across the tumour
samples according to GeNorm, NormFinder, and BestKeeper. The Equivalence test found variation in expression
within a 3-fold expression change between tumour groups for: IPO8, RPL40, RPL30, GUSB, TBP, RPLPO, ACTB, ABL1,
and CDKN1A. However, only IPO8 satisfied at a 2-fold change as a cut-off. Overall, IPO8 and RPL4 had the highest,
whereas GADPH and HPRT1 the lowest expression stability. Employment of suitable reference genes (IPO8, RPL4)
in comparison with unsuitable ones (GADPH, HPRT1), demonstrated divergent influence on the mRNA expression
pattern of our target genes − GPER and uPAR.
Conclusions: We found IPO8 and RPL4 to be suitable reference genes for normalization of target gene expression
in benign, borderline, and malignant ovarian tumours. Moreover, IPO8 can be recommended as a single reference
gene. Neither GADPH nor HPRT1 should be used as reference genes in studies on ovarian tumour tissue.Background
Most cases of ovarian cancer are diagnosed at an ad-
vanced stage, with poor prognosis for the patients. Early
stages of ovarian cancer are, on the other hand, more
accessible to treatment and have much better prognosis.
There is an ongoing search for biomarkers with capacity
to detect in particular early stages of the disease in
screening programs, since this would be the single most
important step towards improving the prognosis. A* Correspondence: Zuzana.Kolkova@med.lu.se
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reproduction in any medium, provided the orselective biomarker might, furthermore, be helpful in the
preoperative assessment of ovarian lesions in order to
employ optimal surgery.
Analysis of gene expression by quantitative real-time
reverse transcription-polymerase chain reaction (RT-
qPCR), a sensitive technique with broad dynamic range,
is a frequent approach for the biomarker discovery in
tumour tissue. However, in order to obtain reliable re-
sults by RT-qPCR in heterogeneous clinical samples, the
expression of a target gene needs to be normalized to a
stably expressed reference gene (RG) to minimize the
influence of variations in, e.g. extraction yield, reverse-
transcription yield, and amplification efficiency [1].l Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Distribution of the primary ovarian tumours
according to histopathology
Serous Mucinous Endometrioid Total
Benign 4 5 9
Borderline 6 5 11
Grade 1 6 2 8
Grade 2 1 3 4
Grade 3 5 5 10
Total 21 13 8 42
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benign and malignant tissues from the specific organ
studied. Use of an unstable reference gene will inevi-
tably produce erroneous results. Needless to say, this
requirement applies also for ovarian tumours with dif-
ferent differentiation grades and histological types.
The traditionally used house-keeping gene, glyce-
raldehyde-3-phosphate dehydrogenase (GADPH), was
reported to display many diverse activities unrelated to
its glycolytic function (e.g. apoptosis and DNA replica-
tion) [2], and to be up-regulated in prostate cancer
already in the 1990s [3]. The most commonly used RT-
qPCR reference genes used for ovarian studies has been
GADPH (~40%), β-actin (ACTB) (~20%), ribosomal
RNA (18S and 28S rRNA) (~10%) and hypoxanthine
phosphoribosyl transferase 1 (HPRT1) (<3%) [4]. More
recent study has advised against the use of GADPH and
ACTB as RG’s, due to their numerous pseudogenes
present in the human genome [5].
Up to now, only two studies have focused on finding a
reliable RG in normal ovarian tissue, and benign and
malignant serous ovarian tumours. The obtained results,
however, differ; Li et al. recommended combination of
GUSB, PPIA, and TBP [4], whereas Fu et al. concluded
that combination of RPL4, RPLPO, and HSP90AB1
(HSPCB) are more suitable [6]. Both studies were per-
formed on Chinese populations, did not include bor-
derline tumours, and used SYBR Green RT-qPCR
technique.
The present study was performed on a Scandinavian
population, included borderline tumours, used prede-
signed commercial RT-qPCR probes, and applied four
different statistical software programs. In addition to the
above mentioned traditionally used and earlier re-
commended RGs for ovarian tissue, we also selected
four genes from a commercially printed array (ABL1,
CDKN1A, IPO8, and RPL30). Thus, altogether 13 genes
we included in the study. Finally, two target genes were
chosen to demonstrate the divergent results, which may
be obtained by normalizing their mRNAs to suitable vs.
unsuitable RGs: G protein-coupled estrogen receptor
(GPER), which has no differences in expression between
benign and malignant ovarian tumours and urokinase
plasminogen activator receptor (uPAR), which is up-
regulated in malignant tumours.
Methods
Ovarian tumour tissue
Tissue samples (n = 42) were obtained from primary
ovarian tumours during surgery at the Department of
Obstetrics and Gynaecology, Lund University Hospital,
during 2001–2007. None of the patients had received
chemotherapy prior to the operation. The samples were
cut in 5 × 5 × 5 mm cubes, quick frozen on dry ice, andstored at −80°C until used. In addition to the routine
histo-pathological examination, each specimen was re-
evaluated by a second pathologist. Histological differen-
tiation was classified as benign (n = 9), borderline (n =
11), and malignant (n = 22); the histological types were
serous (n = 21), mucinous (n = 13), and endometrioid
(n = 8) (Table 1). The mean age of included patients was
59 years (range 22–80) in the benign group, 55 years
(35–86) in the borderline group, and 62 years (43–85) in
the malignant group. The Ethical Review Board at Lund
University Hospital approved the study design and in-
formed consent was obtained from each patient.
Extraction of total RNA
Total RNA was extracted from about 125 mg frozen ova-
rian tumour tissue. The tissue was homogenized in Trizol
50 mg/mL (Invitrogen, Carlsbad, CA) using rotating-
knives (Polytron). All RNA samples were checked for con-
centration and purity by NanoDrop Spectrophotometer
ND-1000 (Saveen Werner, Limhamn, Sweden) having
A260/280 and A260/230 ~ 2. RNA quality and integrity was
verified by Agilent 2100 BioAnalyzer (Agilent Technolo-
gies, Palo Alto, CA), i.e. all samples had RNA Integrity
Number > 7.7.
cDNA synthesis
GeneAmp® RNA PCR kit (Applied Biosystems, Foster
City, CA) was used for reverse transcription of total
RNA (0.2 μg) to cDNA. The final concentration of
cDNA was 1 μg/μL (+/− 7%) and A260/280 ratio ~1.8 as
assessed by NanoDrop. The cDNA samples were stored
at −20°C until further use.
Quantitative RT-qPCR amplification
RT-qPCR was performed using a StepOnePlus™ cycler
(Applied Biosystems) under standard thermal cycling
conditions (activation of contamination preventing en-
zyme at 50°C for 2 min, enzyme activation at 95°C for
10 min, 40 cycles of denaturation at 95°C for 15 s, and
annealing at 60°C for 1 min). PCR reactions were run
in duplicates and negative controls were included in
each amplification set. For each gene analysed, pre-
manufactured real-time qPCR assays were used (Ap-
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Coralville, IA, USA) (Table 2), with probes spanning
exon junctions and not detecting genomic DNA. Using
one malignant tumour sample and a universal human
reference RNA (Stratagene, La Jolla, CA, USA), quanti-
fication experiments were performed using two stan-
dard curves from 10-fold serial dilutions of the cDNA
(80–0.08 ng).Identification of new potential reference genes
In order to identify new candidate reference genes in ova-
rian tumour tissue, we employed a commercial array
(TaqMan® Express Endogenous Control Plate, cat no
4396840, Applied Biosystems) consisting of 32 potential
RGs (18S, GADPH, HPRT1, GUSB, ACTB, B2M, HMBS,
IPO8, PGK1, RPLPO, TBP, TFRC, UBC, YWHAZ, PP
IA, POLR1A, CASC3, CDKN1A, CDKN1B, GADD45A,
PUM1, PSMC4, EIF2B1, PES1, ABL1, ELF1, MT-AT6,
MRPL19, POP4, RPL37A, RPL30, RPS17).
We analysed one benign and one malignant sample of
ovarian tumour, which were selected based on the
greatest difference in expression of traditionally used
RGs (ACTB, GADPH, and HPRT1), as measured by RT-
qPCR. The difference between the threshold cycles (ΔCt)
of the two samples was then calculated for each of theTable 2 Reference genes, target genes and assays used
Gene
symbol
Gene name (synonyms) Function




ACTB Actin, beta Cell motility, structure, integ
CDKN1A Cyclin-dependent kinase inhibitor
1A (p21, Cip1)
Regulation of cell cycle prog
GADPH Glyceraldehyde-3-phosphate
dehydrogenase
Catalysation of an important
step in carbohydrate metabo
GUSB Glucuronidase, beta Degradation of glycosamino
HPRT1 Hypoxanthine phosphoribosyl
transferase 1
Generation of purine nucleo
the purine salvage pathway.
HSP90AB1 Heat shock protein 90 Protein folding, response to
IPO8 Importin 8 Nuclear transport.
PPIA Peptidylprolyl isomerase A
(cyclophilin A)
Protein folding, ligand for Cy
RPL30 Ribosomal protein L30 Component of 60S subunit.
of protein synthesis.
RPL4 Ribosomal protein L4 Component of 60S subunit.
RPLPO Ribosomal protein, large, PO Component of 60S subunit.
TBP TATA box binding protein Initiation of transcription of R
GPER G protein-coupled estrogen
receptor
Rapid estrogen signalling.
uPAR Urokinase plasminogen activator
receptor
Cell invasion, migration, signa32 genes in the array. Four genes with the lowest ΔCt
were selected for inclusion in our main study.
Statistical analysis
Descriptive statistics, F-test for Ct variance equality and
Kolmogorov-Smirnov test for normality of log-trans-
formed relative expression values were calculated by
software SPSS 19.0 (SPSS Inc, Chicago, IL). The Equiva-
lence test [7-9] and statistical applets BestKeeper [10],
geNorm [11], and NormFinder [12] were used for ana-
lysis of genes expression stability. GeNorm calculates a
gene-stability measure, M-value, as the average pair-wise
variation of a particular gene to all other candidate refe-
rence genes [11]. On the other hand, the stability value
calculated with NormFinder combines estimated both
intra-group and inter-group variations [12]. Genes with
the lowest M-values have the most stable expression
(least variability). Relative expression values for target
genes were analysed by Kruskal-Wallis and Mann–
Whitney tests, and the log-transformed values by one-
way ANOVA. P < 0.05 was considered significant.
Results
Selection of best RGs from the commercial gene array
In order to select optimal candidate RGs for this study
on ovarian tumours, ΔCt between one benign and oneNCBI Gene reference Assay ID
adhesion and NM_005157.3, NM_007313.2 Hs00245445_m1
rity NM_001101.3 Hs99999903_m1





tides through NM_000194.2 Hs99999909_m1
stress. NM_007355 Hs.PT.49a.20846338
NM_001190995.1 NM_006390.3 Hs00183533_m1





NA polymerases. M34960.1 M55654.1 Hs99999910_m1
NM_001505.2 Hs00173506_m1
lling via ERK1/2. NM_001005376.2
NM_001005377.2 NM_002659.3
Hs00182181_m1
Kolkova et al. Journal of Ovarian Research 2013, 6:60 Page 4 of 10
http://www.ovarianresearch.com/content/6/1/60malignant ovarian tumour sample with the greatest dif-
ference in expression of the traditionally used RGs
(ACTB, GADPH, and HPRT1), was measured by RT-
qPCR and calculated for all 32 genes included in the ar-
rays. The lowest ΔCt, i.e. the least variation, was found
for CDKN1A (ΔCt: 0.47), ABL1 (0.76), RPL30 (0.83),
RPS17 (1.09), MT-ATP6 (1.42), and IPO8 (1.71), whereas
POP4 (6.11), GADPH (5.04), HPRT1 (4.91), POLR2A
(4.41), CASC3 (3.48) had the highest ΔCt. The most
abundant genes were 18S (mean Ct ± SD: 12.11 ± 1.85)
and MT-ATP6 (21.64 ± 1.00), the genes with lowest ex-
pression were YWHAZ (31.42 ± 2.14) and TBP (31.37 ±
2.06). CDKN1A, ABL1, RPL30 and IPO8 were chosen to
be included in our panel of potential reference genes.
Expression of selected candidate reference and target
genes in primary ovarian tumours
We analysed altogether 13 candidate reference genes
(ABL1, ACTB, CDKN1A, GADPH, GUSB, HPRT1,
HSP90AB, IPO8, PPIA, RPL30, RPL4, RPLPO, and TBP)
and two target genes (GPER and uPAR) by RT-qPCR.
Expression levels and variability of Ct values are shown
for the RGs (Table 3). Of all genes, PPIA had the highest
(mean Ct ± SD: 22.12 ± 0.82) and GUSB the lowest
(31.20 ± 0.99) level of mRNA (Figure 1). The amplifica-
tion efficiencies of the TaqMan-based RT-qPCR assays
were in the range 85–99% for all RGs, except ABL1 and
HPRT1, which had 82% efficiency. The linear regression
coefficient (r2) of the standard curves for all genes
ranged between 0.998 and 1.
Gene expression stability calculated by GeNorm
Expression stability of the 13 candidate RGs was first
assessed by GeNorm in the whole set of tumour sam-
ples. The expression stability value (M-value) was calcu-
lated based on the average pair-wise variation between
all genes tested (Table 4). The genes with the lowestTable 3 Descriptive and correlation analysis of the candidate
ABL1 ACTB CDKN1A GADPH GUSB HPR
n 41 42 42 41 42 41
gM [Ct] 28.05 23.73 28.54 25.39 31.20 29.0
aM [Ct] 28.07 23.75 28.57 25.42 31.23 29.0
min [Ct] 25.90 21.80 26.43 23.02 27.75 26.6
max [Ct] 30.39 25.87 31.23 27.80 34.06 31.9
SD [± Ct] 0.87 0.73 1.05 1.05 0.99 0.9
CV [% Ct] 3.10 3,07 3.69 4.11 3.17 3.1
min [x-fold] −3.62 −3.36 −4.00 −4.33 −10.12 −4.
max [x-fold] 4.04 3.85 5.85 4.41 6.78 5.6
SD [± x-fold] 1.68 1.55 1.88 1.87 1.81 1.7
Geometric mean of Ct (gM [Ct]), arithmetic mean (aM [Ct]), minimum and maximum
coefficient of variance expressed as a percentage on the Ct level (CV [% Ct]), extrem
under- regulation coefficient (min [x-fold], max [x-fold]), and standard deviation ofM-value have the most stable expression and were
ranked as follows: the most stable-IPO8 > RPL4 > TBP >
RPLPO > ACTB > PPIA > HSP90 > HPRT1 > GADPH >
ABL1 > CDKN1A > GUSB > RPL30.
Gene expression stability calculated by NormFinder
M-values were calculated for individual RGs using
NormFinder that assessed the expression stability by
combining estimated inter- and intra-group variation
(Table 4). The genes were ranked according to expres-
sion stability as follows: the most stable-TBP > RPLPO >
IPO8 > ACTB > RPL4 > PPIA > HSP90 > GADPH >
HPRT1 > CDKN1A > RPL30 > GUSB > ABL1. The five
best-ranked genes — TBP, RPLPO, IPO8, ACTB, and
RPL4 — turned out to be the same five most stable
genes found by GeNorm.
Moreover, NormFinder allowed stability analysis be-
tween subgroups: 1) benign, 2) borderline, 3) malignant,
4) serous benign and borderline tumours 5) mucinous,
benign and borderline tumours, 6) serous malignant
tumours, and 7) endometrioid malignant tumours
(Table 5). Combining the two most stable genes fur-
ther improved the M-value in group-wise comparison.
In all obtained combinations, IPO8 followed by RPL4
came out as the most stable genes.
Analysis of expression stability by BestKeeper and
equivalence test
In the next step, candidate RGs were evaluated by
BestKeeper and the Equivalence test for variations in ex-
pression in the whole data set and between tumours
groups as described above. IPO8 had the lowest stan-
dard deviation (SD) of the Ct value across the groups
(mean Ct ± SD: 29.10 ± 0.65). The best-ranked genes by
GeNorm and NormFinder — IPO8, ACTB, TBP, RPL4,
and RPLPO — fulfilled the BestKeeper criteria for sta-
bility variation of the Ct value with SD < 1 (Table 3).RGs obtained by BestKeeper
T1 HSP90 IPO8 PPIA RPL30 RPL4 RPLPO TBP
42 42 42 42 42 42 42
2 26.81 29.10 22.12 28.78 25.88 24.86 28.70
4 26.84 29.11 22.15 28.81 25.90 24.88 28.71
3 24.30 27.48 19.91 26.34 23.79 22.91 27.28
1 29.55 30.64 24.53 31.06 27.98 26.66 31.55
1 0.86 0.65 0.82 1.09 0.77 0.81 0.75
3 3.19 2.22 3.71 3.78 2.98 3.27 2.62
17 −5.66 −2.76 −4.17 −4.53 −3.79 −3.37 −2.62
4 6.62 2.61 4.73 4.11 3.82 3.06 6.15
2 1.67 1.47 1.63 1.96 1.61 1.66 1.59
values of Ct (min [Ct], max [Ct]), standard deviation of Ct (SD [± Ct]),
e values of expression levels expressed as an absolute x-fold over- or
the absolute regulation coefficients (SD [± x-fold]).
Figure 1 Expression levels of 13 candidate reference genes in benign (BE), borderline (BO), and malignant (MA) primary ovarian
tumours. Values are given as the cycle threshold (Ct) and are inversely proportional to the amount of template. Expression levels of the genes
studied are shown as whiskers box plots.
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criteria.
Further, we applied the Equivalence test including both
cut-offs of 2-fold and 3-fold expression change to iden-
tify the best candidates according equivalent expression
in group-wise comparison (Figure 2) [8]. The Equiva-
lence test criteria at 3-fold expression change were ful-
filled for IPO8, RPL4, RPL30, GUSB, TBP, RPLPO,Table 4 Ranking of 13 candidate RGs according to their
expression stability by GeNorm and NormFinder
GeNorm NormFinder
Gene M-value Gene M-value
IPO8 0.55 TBP 0.225
RPL4 0.55 RPLPO 0.251
TBP 0.58 IPO8 0.253
RPLO 0.60 ACTB 0.264
ACTB 0.62 RPL4 0.272
PPIA 0.65 PPIA 0.339
HSP90 0.67 HSP90 0.357
HPRT1 0.72 GADPH 0.373
GADPH 0.77 HPRT1 0.396
ABL1 0.86 CDKN1A 0.433
CDKN1A 0.93 RPL30 0.441
GUSB 1.00 GUSB 0.444
RPL30 1.10 ABL1 0.515ACTB, ABL1, and CDKN1A in all subgroups (Table 6).
GAPDH was stably expressed only in two out of the five
subgroups, followed by HPRT1, HSB90AB1, and PPIA
that were equivalently expressed in three subgroups
using cut-off of 3. However, IPO8 was the only gene
with equivalent expression within 2-fold change in all
subgroups.Interpretation of target genes expression
In order to show the effect of the unstable RGs on the
final expression of target genes, GPER and uPAR
mRNAs were related to either IPO8 and RPL4, or
GADPH and HPRT1 mRNA. The choice of target genes
was based on our previous observations that GPER
mRNA expression did not show any variation between
benign, borderline, and malignant ovarian tumour sam-
ples [13], whereas uPAR mRNA was higher in borderline
and malignant than benign ovarian tumour samples [14].
In accordance with our previously published results,
the tissue content of GPER mRNA normalized to IPO8
or RPL4 mRNA showed no significant differences be-
tween benign, borderline, and malignant tumour sam-
ples. In contrast, GPER mRNA normalized to GADPH
or HPRT1 mRNA was higher in benign and borderline
tumours than in malignant tumours (Figure 3). uPAR
mRNA normalized to IPO8 or RPL4 was significantly
up-regulated in borderline and malignant tumours as
compared to benign tumours, whereas when it was
Table 5 NormFinder ranking of 13 candidate RGs and combinations of the two best in group-wise comparison
Gene name BE × BO × MA BE + BO × MA BE × BO + MA BE × MA Ser × Muc (BE + BO) Ser × End (MA)
ALB1 13 13 13 13 9 9
ACTB 2 4 6 5 7 4
CDKN1A 12 12 8 8 12 11
GADPH 8 9 11 11 10 10
GUSB 7 7 12 12 11 12
HPRT1 10 8 7 7 8 5
HSP90 6 11 5 6 2 8
IPO8 5 3 2 1 1 2
PPIA 9 10 9 9 4 3
RPL30 11 6 10 10 13 13
RPL4 1 1 3 2 3 7
RPLPO 4 2 4 3 6 6
TBP 3 5 1 4 5 1
Best combination RPL4/ACTB RPL4/RPLPO IPO8/TBP IPO8/RPL4 IPO8/HSP90 IPO8/TBP
M-value 0.104 0.088 0.060 0.079 0.060 0.073
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differences between the tumour groups (Figure 4).
Discussion
Although RT-qPCR is the most commonly used method
for assessing gene expression, in-depth studies of poten-
tial reference genes and their expression pattern in ovar-
ian tumour tissue are insufficient. The aim of this study
was to identify the most stably expressed RGs, which
can be recommended for normalization of RT-qPCR re-
sults in benign, borderline and malignant ovarian tu-
mour samples.
We analysed the traditionally used RGs, those reported
as being suitable for ovarian tissue, and the four most
promising genes from a commercial RG array. Alto-
gether 13 potential reference genes were tested for sta-
bility across groups of benign, borderline, and malignant
primary ovarian tumours of different histological sub-
types. Of the genes studied, IPO8, RPL4, TBP, RPLPO,
and ACTB were found to be the most stable according
to the statistical applets GeNorm, NormFinder and
BestKeeper. Our findings on RPL4, RPLPO, and TBP in
a Scandinavian population are in accordance with previ-
ous reports in Asian populations [4,6]. In contrast, our
results did not support PPIA as suitable RG, which has
been observed previously [4]. With regard to the hetero-
geneity of ovarian tumour materials and different rank-
ing results produced by the commonly used statistical
approaches, we decided to further employ the Equiva-
lence test in our analysis. By applying strict criteria in
the Equivalence test, i.e. only allowing a 2-fold change of
expression, we could identify IPO8 expression as the
most stable of all candidate genes tested.We included IPO8 in our study because it showed low
variation in expression between the benign and the ma-
lignant sample in the commercial array. This gene was
equivalently expressed across the tumour subgroups of
different malignant potential and histology. IPO8 is a
Ran-binding protein mediating nuclear import [15] and
has been already reported stably expressed in lung tis-
sues [16], gliomas [17], and colon cancer [18].
The second best RG for group-wise comparison,
RPL4, encodes a protein that is a component of the 60S
ribosome subunit [19]. Apart from ovarian tissue, it has
previously been recommended as RG in combination
with PGK1 for exfoliated cervical cells [20]. RPLPO, an-
other gene from the ribosomal protein family, had stable
expression in HPV-positive as in HPV-negative cervical
samples [21] and in tamoxifen or estrogen treated breast
cancer cells [22]. TBP, a key regulator of gene expres-
sion, has previously been identified as a suitable RG for
expression studies on human hepatitis B virus-related
hepatocellular carcinoma [23], human renal cell carci-
noma [24], and glioblastomas [17]. RPLPO and TBP also
belonged to one of the most stably expressed genes in
breast carcinomas [25].
Two other candidates that have not previously been
tested as RGs in ovarian tumour tissue, ABL1 and
CDKN1A, were selected from the commercial gene
array. Both genes satisfied the Equivalence test at 3-fold
expression change. ABL1, originally identified as a ho-
mologue of the transforming gene of the Abelson mur-
ine leukemia virus, is a proto-oncogene, which has been
implicated in mitogenesis, regulation of gene transcrip-
tion, and inhibition of apoptosis [26]. Nucleotide poly-
morphism in the ABL1 gene has been associated with
Figure 2 Variation in expression of 13 candidate reference genes analysed by Equivalence test between tumour groups. Differences of
the means (♦) and matching symmetrical confidence intervals (-) are shown for the log2-transformed relative gene expression. Y-axis represents
the fold change in expression among subgroups. The deviation area [-l; l] for a fold change ≤2 lies within the dashed lines; the deviation area
[-2; 2] for a fold change ≤3 lies within the solid lines. The gene is considered to be equivalently expressed, if the symmetrical confidence interval
is a part of the deviation area and contains 0 in it. The variation in expression of the 13 reference genes was compared between benign vs.
borderline and malignant tumours (A), benign and borderline vs. malignant tumours (B), benign vs. malignant tumours (C), mucinous vs. serous
benign and borderline tumours (D), and serous vs. endometrioid malignant tumours (E).
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p21) was initially described as an inhibitor of cancer cell
proliferation [27]. However, recent studies suggest that it
has dual functions since it also may promote tumour
progression [28] and be associated with cisplatin resis-
tance in ovarian cancer [29].
According to BestKeeper and Equivalence test criteria,
we found that GADPH had the worst expression stability
in our set of ovarian tumour samples. Similar unfavou-
rable results were obtained for HPRT1. These observa-
tions are in line with previous studies on other tissuetypes that have discouraged use of GADPH and HPRT1
as RGs for clinical lung specimens [16] and renal cell
cancer [24]. Most recently, a microarray study identified
a group of genes highly correlated to GADPH up-
regulation in various solid tumours, which were and
proportionally associated with advanced stages [30]. Pre-
vious reports on GADPH in ovarian tissue have either
pointed out higher expression in malignant than in
benign tumours and normal tissue [6], or not meeting
the GeNorm stability criteria [4]. We further demon-
strated that employment of GADPH or HPRT1 for
Table 6 Expression stability of the candidate RGs analysed by equivalence test
BE × BO + MA BE + BO × MA BE × MA Ser × Muc (BE + BO) Ser × End (MA) Total passes 2-fold/3-fold
ABL1 0 /1 0 /1 0 /1 1 /1 0 /1 1 /5
ACTB* 0 /1 0 /1 0 /1 1 /1 0 /1 1 /5
CDKN1A 0 /1 1 /1 0 /1 0 /1 0 /1 1 /5
GADPH 0 /0 0 /0 0 /0 0 /1 0 /1 0 /2
GUSB 0 /1 0 /1 1 /1 1 /1 0 /1 2 /5
HPRT1 0 /1 0 /0 0 /0 0 /1 0 /1 0 /3
HSP90 0 /1 0 /0 0 /0 0 /1 0 /1 0 /3
IPO8* 1 /1 1 /1 1 /1 1 /1 1 /1 5 /5
PPIA 0 /1 0 /0 0 /0 1 /1 0 /1 1 /3
RPL30 1 /1 0 /1 0 /1 0 /1 1 /1 2 /5
RPL4* 1 /1 0 /1 0 /1 0 /1 1 /1 2 /5
RPLPO* 0 /1 0 /1 0 /1 0 /1 1 /1 1 /5
TBP* 1 /1 0 /1 0 /1 0 /1 1 /1 2 /5
The expression within (1) or outside (0) 2-fold/3-fold expression change cut-off and the total number of meeting the cut-off criteria in the five subgroups.
* Genes best-ranked by GeNorm, NormFinder and BestKeeper.
Figure 3 GPER mRNA assayed and normalized to IPO8, RPL4, GADPH, and HPRT1 mRNA. Ovarian tumours were sub-grouped according to
the histological malignant potential as benign (BE, n = 9), borderline (BO, n = 11) and malignant (MA, n = 22). Normalization to IPO8 and RPL4
showed no significant variation of the GPER mRNA content between BE, BO and MA tumours (A, B). In contrast, GPER mRNA was higher in
BE/BO compared to MA when normalized to GADPH (p = 0.002) or HPRT1 (p = 0.008) (C, D).
Kolkova et al. Journal of Ovarian Research 2013, 6:60 Page 8 of 10
http://www.ovarianresearch.com/content/6/1/60
Figure 4 UPAR mRNA assayed and normalized to IPO8, RPL4, GADPH, and HPRT1 mRNA. Ovarian tumours were sub-grouped according to
the histological malignant potential as benign (BE, n = 9), borderline (BO, n = 11) and malignant (MA, n = 21). uPAR mRNA content was higher in
BO/MA than in BE when related to IPO8 (p = 0.003) and RPL4 (p = 0.001) (A, B). No significant differences were found in the amount of uPAR
mRNA when it was normalized to GADPH or HPRT1 mRNA (C, D).
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expression of target genes.
To our knowledge, this is the first report on RGs in
ovarian tumours that include borderline tumours in
addition to benign and malignant tumours. Since they
are considered a non-invasive pre-stage of molecular
type I ovarian cancer, it is important to include them in
any study on biomarker discovery [31].
Ovarian cancer comprises tumours of different morph-
ology and pathogenesis, which may have different gene
expression profiles [32]. Therefore we wished to see
whether the histology of ovarian tumours influences the
stability of RGs. Thus, in contrast to the previous
studies conducted exclusively on serous malignant tu-
mours, our study also included mucinous and endo-
metrioid tumours. However, small number of samples
in some groups limited the comparisons that could
be performed.Conclusions
In conclusion, thorough statistical evaluation of our 13
candidate RGs identified IPO8 followed by RPL4 as the
most suitable for the normalization of gene expression
data in benign, borderline, and malignant ovarian tu-
mours. For the first time, IPO8 is presented as the best
normaliser for gene expression studies on ovarian tumour
tissue with heterogeneous histology when used as a single
RG. Neither GADPH nor HPRT1 should be used as RGs
for ovarian tissue studies, because of poor expression
stability. Normalizing to these genes may erroneously
influence the quantification of the target gene(s) and
hence reduce the reliability of the RT-qPCR results.
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